版本:
中国

BRIEF-Zosano Pharma updates on additional data from Zotrip study

June 12 Zosano Pharma Corp:

* Says presents additional data from Zotrip study

* Zosano pharma says 3.8 mg dose of of M207 achieved significance in secondary endpoints of pain freedom at 45 minutes and 1 hour

* Says 3.8 mg dose of M207 showed durability of effect on pain freedom at 24 and 48 hours

* Data demonstrated that the results were attained with no serious adverse events and a favorable tolerability profile Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐